Drug intelligence / Profile preview

Treatment Set TS338618

Development stage: Unknown
Administration: Intradermal, Subcutaneous

Overview

Treatment Set TS338618 is an allergen extract formulation administered via intradermal and subcutaneous injection. It is a solution intended for use in allergen immunotherapy for treating allergies. The product is classified as a human prescription drug under BLA102223 and became effective on December 1, 2010[1][3]. Individual allergenic extract treatment vials are intended for use by physicians who are experienced in the administration of allergenic extracts[5]. The treatment set contains allergen extracts for diagnostic testing and therapeutic desensitization.

Beyond the preview

Go deeper on Treatment Set TS338618.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treatment Set TS338618.

Explore the full profile